Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered papers 3 - Best abstracts

128O - PDL1/CD274 gain/amplification as a predictive marker of checkpoint blockade inhibitor efficacy in metastatic breast cancer: Exploratory analysis of the SAFIR02-IMMUNO randomized phase II trial

Date

24 May 2020

Session

Proffered papers 3 - Best abstracts

Presenters

Thomas Bachelot

Citation

Annals of Oncology (2020) 31 (suppl_2): S58-S61. 10.1016/annonc/annonc121

Authors

T. Bachelot1, T. Filleron2, F. Dalenc3, I. Bieche4, I. Gaberis5, E. Rouleau5, A. Tran-Dien5, J. Adam6, A. Lusque2, M. Jimenez7, A. Jacquet7, F. André8

Author affiliations

  • 1 Centre Léon Bérard, Centre Léon Bérard, 69008 - Lyon/FR
  • 2 Biostatistics, Centre Claudius-Regaud, 31052 - Toulouse/FR
  • 3 Centre Claudius-regaud, Centre Claudius-Regaud, 31052 - Toulouse/FR
  • 4 Institut Curie, Institut Curie, 75005 - PARIS/FR
  • 5 Gustave Roussy, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 6 Pathology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 7 R&d, UNICANCER, 75654 - Paris/FR
  • 8 Breast Cancer Unit, Medical Oncology Department, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
More

Resources

Login to access the resources on OncologyPRO.

Abstract 128O

Background

PD(L)1 inhibitor have shown efficacy for limited sub population of patients (pts) with HER2 negative metastatic breast cancer (MBC). The main predictive marker of efficacy to date are the absence of ER and PR receptor, and pdl1 positivity by IHC. We investigated copy number alteration (CNA) of the PDL1 gene (also named CD274) located at 9p24.1 in the SAFIR02 Breast Immuno randomized phase II trial (NCT02299999).

Methods

SAFIR02 BREAST IMMUNO randomized 199 pts presenting a MBC without actionable genomic alterations, responding to 6 months standard chemotherapy, either on durvalumab (10 Mg/kg every two weeks) or on maintenance chemotherapy with a 2:1 ratio. Eighty-two (43%) pts had a triple negative (TN) MBC. Using metastatic tumor samples, PDL1 CNA were characterized from array CGH analysis (Affymetrix CytoscanHD or Oncoscan). A gain of copy number was defined as 3–4 copies and an amplification ≥ 5 copies. Treatment effect was estimated in each subgroup using a cox proportional hazard model.

Results

For PDL1 CNA were available for 153 pts (101 immuno, 52 chemotherapy). PDL1 copy loss, neutral, or copy gain/amplification were reported on 30 (20%), 93 (61%) and 30 (20%) of pts, respectively. Pts with TN MBC had a higher proportion of gain/amplification (23/65 pts, 35% for TN tumors; vs 7/82, 8.5% for non-TN). Improvement of OS with durvalumab was limited to the PDL1 CNA gain/amplification subgroup (HR = 0.17, 95% CI 0.05-0.55) with a median OS of 9 months (95%CI 4-18) in maintenance arm and not reached in durvalumab arm. Among pts with TN tumors, durvalumab was associated to a better OS in the gain/amplification subgroup (HR 0.18, 95%CI 0.05-0.71 ), compared to the neutral/loss subgroup (HR 1.1, 95%CI 0.47-2.6 ).

Conclusions

This exploratory subgroups analysis of the first randomized trial comparing a PDL1 inhibitor to chemotherapy in the maintenance setting shows that PDL1 CNA could be an important predictive marker for PD(L)1 inhibitors efficacy. If confirmed on larger series, it could have an important implication on the development of immunotherapy for MBC pts, in particular for subgroups with low immunogenicity such as the luminal subtype.

Clinical trial identification

NCT02299999; 2013-001652-36.

Editorial acknowledgement

This research was conducted with support from an "Investigator Sponsored Study¨Programme by AstraZeneca".

This research was conducted with support from Fondation ARC.

Legal entity responsible for the study

Unicancer.

Funding

Fondation ARC, AstraZeneca.

Disclosure

T. Bachelot: Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Seattle Genetic; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Lilly; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca. F. Dalenc: Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Lilly; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Eisai; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca. F. André: Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Daiichi Sankyo; Leadership role, Founder: Pegacsy. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings